Whalesbook
GSP Crop Science Ltd's ₹400 crore initial public offering (IPO) is seeing divided investor demand on its second day of bidding. By midday on March 17, 2026, the IPO was 65% subscribed. Demand is mainly from Qualified Institutional Buyers (QIBs), who subscribed 1.28 times their share, and Non-Institutional Investors (NIIs), who were close to fully subscribed at 0.93 times. This contrasts sharply with retail investors, who have subscribed only 0.15 times their quota. The uneven participation suggests institutions favor the company's debt reduction plans, while some retail investors remain hesitant, possibly over valuation or sector risks. The IPO's grey market premium (GMP) currently stands at ₹0, indicating market expectations for a flat listing.
GSP Crop Science operates in India's agrochemical sector, which is forecast to grow at a 13% annual rate through 2030, reaching over $13 billion by 2031. The company's IPO is priced between ₹304 and ₹320 per share, valuing it at approximately ₹1,489 crore at the upper band. This valuation translates to a Price-to-Earnings (P/E) ratio of around 18.3x for FY25 earnings. While this is competitive compared to larger players like PI Industries (P/E ~30.4x) and UPL Ltd (P/E ~23.94x), it is at a premium to some domestic-focused peers like Dhanuka Agritech. The company plans to use ₹170 crore from IPO proceeds for debt repayment to strengthen its finances. GSP Crop Science has a diversified product range including insecticides, herbicides, fungicides, and plant growth regulators, serving both domestic and international markets. However, the sector faces risks from monsoon patterns, with forecasts of a weaker monsoon in 2026 due to El Niño, potentially impacting farm activity and demand for its products.
Despite institutional support and a positive sector outlook, significant risks remain. The muted retail subscription for GSP Crop Science echoes a wider caution among smaller investors in the 2026 IPO market, where many recent listings have performed poorly. While the valuation seems reasonable compared to some larger rivals, retail investors might see it as expensive, especially given the agrochemical business's cyclical nature and demand volatility linked to weather, like the predicted weaker monsoon for 2026. The agrochemical industry is also highly regulated, with dependence on timely product registrations and approvals posing an ongoing challenge. Competition within the sector remains intense. The company's significant promoter shareholding post-IPO could also centralize influence over corporate decisions.
Investors will closely watch final subscription numbers by the March 18, 2026 closing date to gauge overall appetite. The current demand split suggests the stock's listing performance on March 24, 2026, may rely heavily on sustained institutional support to balance out retail hesitancy. Brokerage firms like BP Equities and Marwadi Financial Services recommend 'subscribe,' citing the company's diverse products and fair valuation. However, SBI Securities views the issue as fully priced, pointing to risks from seasonal demand and input costs. The IPO's success and subsequent trading performance will likely depend on GSP Crop Science's ability to manage sector challenges and achieve its debt reduction and growth goals in a generally cautious 2026 market for new listings.